Monday, December 20, 2021
Monomer-Dimer Hybrid Immunoconjugates
Scott K. Reed
Bioverativ Therapeutics Inc., Genzyme Corporation, Genzyme Europe B.V., Bioverativ U.S. LLC, and Bioverativ Pacific LLC
Letter to Lisa R. Barton, Secretary, USITC; requesting that the Commission conduct an investigation under section 337 of the Tariff Act of 1930, as amended, in the matter of certain monomer-dimer hybrid immunoconjugates. The proposed respondents are Hanmi Pharmaceutical Co., Ltd., Korea; and Spectrum Pharmaceuticals, Inc., Henderson, NV.